Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Reproductive And Gender Health topic
No spam. Unsubscribe anytime.
Two bills: expanded coverage for fertility and gender-affirming care (H55) and a state medication stockpile (H56) presented
Summary
Representative Troy Hedrick presented H55 to expand insurance coverage for fertility services and gender-affirming care (with Medicaid inclusion contingent on federal approval) and H56 to establish a Department of Health stockpile of reproductive and gender-affirming medications for emergencies and supply interruptions.
Representative Troy Hedrick presented two separate bills to the House Health Care Committee. H55 would expand private insurance and Medicaid coverage (Medicaid contingent on federal approval) for gender-affirming health care and fertility-related services and would prohibit certain insurance-imposed barriers, such as requirements for prolonged hormone therapy prior to surgery. The bill would exclude nonmedical costs (egg/sperm donors, surrogacy) and would require the Department of Financial Regulation to report annually on compliance and access.
Hedrick said the bill is designed to reduce barriers and promote equity for Vermonters seeking these services. "Expanding coverage for these services supports health equity, affordability, and aligns Vermont laws with current best practices in health care," he told the committee.
H56 would require the Vermont Department of Health to establish and maintain an emergency stockpile of essential medications for reproductive and gender-affirming care — examples Hedrick cited included puberty blockers, hormone therapies, contraceptives and medications used for pregnancy termination. The stockpile would prioritize equitable distribution to rural and underserved communities, be managed with inventory-rotation protocols to avoid waste, and include annual reporting to the Legislature. The bill would not compel private pharmacies or providers to dispense from the stockpile and would not alter the legal access framework for these medications.
Hedrick said the stockpile is designed to address supply-chain disruptions and potential policy-driven shortages in other states or at the manufacturer level. He said funding details remain to be worked out and that the Department of Health would develop procurement and distribution rules.
Committee members acknowledged the policy rationale and noted the fiscal and implementation questions to be addressed when the bills are scheduled for testimony; no committee vote occurred at this meeting.
